anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== International expansion === On May 12, 1983, Domino's opened its first international store, in Winnipeg, Manitoba, Canada. That same year, Domino's opened its 1,000th store, at 8086 E. Mill Plain Blvd. in Vancouver, Washington. In 1985, the chain opened their first store in the United Kingdom in Luton. Also, in 1985 Domino's opened their first store in Tokyo, Japan. In 1993, they became the second American franchise to open in the Dominican Republic and the first one to open in Haiti, under the direction of entrepreneur Luis de Jesús Rodríguez. By 1995, Domino's had expanded to 1,000 international locations. In 1997, Domino's opened its 1,500th international location, opening seven stores in one day across five continents. By 2014, the company had grown to 6,000 international locations and was planning to expand to pizza's birthplace, Italy; this was achieved on October 5, 2015, in Milan, with their first Italian location. CEO Patrick Doyle, in May 2014, said the company would concentrate on its delivery model there. After having faced tough competition from local restaurants and falling behind on its debt obligations, Domino's exited the country in 2022. In 1995, Domino's Pizza entered China through the Pizza Vest Fast Food Group, which also owned the rights to operate Domino's Pizza in eleven Southeast Asian countries. In February 2016, Domino's opened its 1,000th store in India. Outside the United States, India has the largest number of Domino's outlets in the world.
The Ainu people inhabited the Kuril Islands from early times, although few records predate the 17th century. From the Kamakura period to the Muromachi period, there were Ezo (Ainu) people called Hinomoto from the Pacific coast of Hokkaido to the Kuril region, and Mr. Ando, the Ezo Sateshiku and Ezo Kanrei, was in charge of this ("Suwa Daimyojin Ekotoba"). It is said that when turmoil broke out on Ezogashima, he dispatched troops from Tsugaru. Its activities include the Kanto Gomensen, which calls itself the Ando Suigun, and is based in Jusanminato ("Kaisen Shikimoku"), supplying Japanese products to Ezo society and purchasing large quantities of northern products and shipping them nationwide. ("Thirteen Streets"). The Matsumae clan, a feudal lord of Japan, became independent from the Ando clan (the family of Goro Ando). The Japanese administration first took nominal control of the islands during the Edo period (1603–1868) in the form of claims by the Matsumae clan. The Shōhō Era Map of Japan (Shōhō kuni ezu (正保国絵図)), a map of Japan made by the Tokugawa shogunate in 1644, shows 39 large and small islands northeast of Hokkaido's Shiretoko Peninsula and Cape Nosappu. A Dutch expedition under Maarten Gerritsz Vries explored the islands in 1643. Fedot Alekseyevich Popov sailed into the area c. 1649. Russian Cossacks landed on Shumshu in 1711. American whaleships caught right whales off the islands between 1847 and 1892. Three such ships were wrecked on the islands: two on Urup in 1855 and one on Makanrushi in 1856.
Risk of developing CJD increases with age. CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017. Approximately 85% of CJD cases are sporadic, and 10–15% of CJD cases are due to inherited mutations of the prion protein gene. CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017. Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months. According to a 2020 systematic review on the international epidemiology of CJD:
3-Dehydrocarnitine has a role as a human metabolite, as it is an intermediate of the degradation of carnitine. Carnitine is utilized in the transport of fatty acids from the cytosol into the mitochondria of living cells during the breakdown of fatty acids for the generation of metabolic energy. In humans, 3-dehydrocarnitine is found in the blood, saliva, urine, and feces. In patients with colorectal cancer, elevated levels of 3-dehydrocarnitine have been detected, possibly due to the elevated rate of metabolism seen in malignant cancer cells. 3-Dehydrocarnitine is also found exogenously in multiple sources of food, such as poultry, lagomorph, sheep, goat, beef, venison, equine, and pork. This indicates its presence in the animals the food is derived from. 3-Dehydrocarnitine is also present in mice and Apis cerana. It is found as a metabolite in aging mouse brains, and is found as a product of Apis cerana.
Sources: en.wikipedia.org
A nonradioactive zirconium sample can be extracted from spent fuel by extracting strontium-90 and allowing enough of it to decay (e.g. in an RTG). The zirconium can then be separated from the remaining strontium leaving a very isotopically pure Zr-90 sample.
In physics, the first law of thermodynamics is an expression of the conservation of total energy of a system. The increase of the energy of a system is equal to the sum of work done on the system and the heat added to that system:
=== Rebuild === In 2022, the Development Bank of Southern Africa (DBSA) was appointed to lead a rebuild of the parliament buildings. An initial estimate of R2.2 billion for the rebuild in 2024 ballooned to R4.6 billion in 2025. The rebuild includes the 1983 National Assembly building, the Old Assembly Building, and the 90 Plein Street offices. In August 2026, members of the Joint Standing Committee on the Financial Management of Parliament visited Parliament's construction site to assess the rebuild's progress. During a committee meeting, it was noted that the project was still within budget, with R2.43 billion of the total R4.68 billion having been spent so far. The rebuild was on track to finish by its target date of June 2027, before that year's SONA. According to the project's implementing agent, the Development Bank of Southern Africa (DBSA), construction of the new National Assembly building was 76% complete at the time.
Protein synthesis, as any other of the 20 proteinogenic amino acids Lipid synthesis, especially by cancer cells. Regulation of acid-base balance in the kidney by producing ammonium Cellular energy, as a source, next to glucose Nitrogen donation for many anabolic processes, including the synthesis of purines Carbon donation, as a source, refilling the citric acid cycle Nontoxic transporter of ammonia in the blood circulation.
=== Food packaging === Nylon resins are used as a component of food packaging films where an oxygen barrier is needed. Some of the terpolymers based upon nylon are used every day in packaging. Nylon has been used for meat wrappings and sausage sheaths. The high temperature resistance of nylon makes it useful for oven bags.
Sources: en.wikipedia.org
Initially, pyruvate and thiamine pyrophosphate (TPP or vitamin B1) are bound by pyruvate dehydrogenase subunits. The thiazolium ring of TPP is in a zwitterionic form, and the anionic C2 carbon performs a nucleophilic attack on the C2 (ketone) carbonyl of pyruvate. The resulting intermediate undergoes decarboxylation to produce an acyl anion equivalent (see cyanohydrin or aldehyde-dithiane umpolung chemistry, as well as benzoin condensation). This anion attacks S1 of an oxidized lipoate species that is attached to a lysine residue. In a ring-opening SN2-like mechanism, S2 is displaced as a sulfide or sulfhydryl moiety. Subsequent collapse of the tetrahedral intermediate ejects thiazole, releasing the TPP cofactor and generating a thioacetate on S1 of lipoate. The E1-catalyzed process is the rate-limiting step of the whole pyruvate dehydrogenase complex.
After electrophoresis is complete, the molecules in the gel can be stained to make them visible. DNA may be visualized using ethidium bromide which, when intercalated into DNA, fluoresce under ultraviolet light, while protein may be visualised using silver stain or Coomassie brilliant blue dye. Other methods may also be used to visualize the separation of the mixture's components on the gel. If the molecules to be separated contain radioactivity, for example in a DNA sequencing gel, an autoradiogram can be recorded of the gel. Photographs can be taken of gels, often using a gel doc system. Gels are then commonly labelled for presentation using a number of tools, such as Adobe Illustrator, GIMP, ImageJ, Microsoft PowerPoint, and sciugo.
=== Signs === There are many different signs of dehydration in undernourished people. These can include sunken eyes; a very dry mouth; decreased urine output or dark urine; increased heart rate with decreasing blood pressure; and altered mental status.
The two substrates of this enzyme are (5β)-pregnan-21-ol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (5β)-pregnan-21-al, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 21-hydroxysteroid:NAD+ 21-oxidoreductase. This enzyme is also called 21-hydroxysteroid dehydrogenase (NAD+).
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.